Growth Hormone Deficiency (GHD) - Pipeline Assessment and Market Forecasts to 2017 The GHD Therapeutics Market is Forecast to Grow Until 2017 The global Growth Hormone Deficiency (GHD) therapeutics market was worth $2.7 billion in 2009. The market is expected to grow by a CAGR (Compound Annual Growth Rate) of 2.78% during the next eight years, to reach $3.4 billion by 2017. The GHD market has been well served by synthetic growth hormone (GH), GH regulators and GH secretagogues. The major marketed products for GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These are indicated for the treatment of GHD in adults and children and have an average efficacy of about 80% (overall, considering the high efficacy in children and moderate efficacy in adults), and also a good safety profile. The treatment of GHD in adults seems less effective through these options. The growth hormones are injectables. This means even a once-a-day dose will not ensure compliance as it is inconvenient to patients. Companies are now focusing on adult GHD, which will enable them to reap revenues from this growing market. The primary focus would be to provide safer and more efficacious products, with improved formulations to reduce the frequency of administration. LG Life Sciences, Althea Technologies, Ambrx Inc., Novo Nordisk and Ipsen are believed to be working on the same method of meeting the unmet need in the market. The global GHD market is heading towards a phase of continuous but slow growth. Genotropin will lose its patent in April 2013 because of which the market growth is lowered. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Growth-Hormone-Deficiency-Pipeline-Assessment-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare The level of competition in the GHD market is strong. The current pharmacological therapies involve the administration of GH for the treatment of GHD both in adult and pediatric patients. However, these therapies seem to be less effective in adult patients. The biosimilars used to treat GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These agents are either GH secretagogues, synthetic hGH or GH releasers. The current market is well served by the present treatment options available, but the efficacy of treatment for adult patients is moderate which creates an opportunity for the launch of new targeted therapies to address the unmet need. Most of the marketed products available for the treatment of GHD are dosed once daily, which is inconvenient to patients. This has been cited as the major reason for patients’ non-compliance to therapy. Thus, there is an urgent need for therapies which can decrease the frequency of administration and at the same time demonstrate improved safety over the currently marketed products.
GlobalData’s report, “Growth Hormone Deficiency - Drug Pipeline Assessment and Market Forecasts to 2017�, is an essential source of information and analysis on the global groeth hormone deficiency (GHD) market. The report identifies the key trends shaping and driving the global GHD market. The report also provides insights into the prevalent competitive landscape and the emerging players expected to alter the market position of the current market leaders. Most importantly, the report provides valuable insights into the pipeline products in the global Growth Hormone Deficiency segment. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Growth-Hormone-Deficiency-Pipeline-Assessment-and-Market-Forecasts-to2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuti cals_and_Healthcare Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782